Search Result

Results for "

Melanoma Metastasis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (1) Bacterial (2) Endogenous Metabolite (1) Fungal (2) HIF/HIF Prolyl-Hydroxylase (1) ICMT (56) LPL Receptor (1) Microtubule/Tubulin (1) MMP (1) NF-κB (1) Parasite (2) Phosphodiesterase (PDE) (1) PPAR (2) Ras (1) RIP kinase (1) ROCK (2) SDCBP (1) Toll-like Receptor (TLR) (1)
By Research Areas:	Cancer (70) Infection (2) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: AIM2

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-121524

DJ101	Microtubule/Tubulin	Cancer
DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research .

HY-121750

CCG-222740	Ras ROCK	Cancer
CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor . CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis .

HY-B0963

Cloxiquine 5-Chloro-8-quinolinol	Bacterial Fungal Parasite PPAR	Infection Cancer
Cloxiquine (5-Chloro-8-quinolinol) is an antibacterial, antifungal and antiamoebic agent. Cloxiquine can be used for the research of tuberculosis and dermatoses. Cloxiquine suppresses the growth and metastasis of melanoma cells through activation of PPARγ .

HY-156483

TT-012	Others	Cancer
TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .

HY-119933

RIPK1-IN-7	RIP kinase	Cancer
RIPK1-IN-7 is a potent and selective RIPK1 inhibitor with a K_d of 4 nM and an enzymatic IC₅₀ of 11 nM. RIPK1-IN-7 exhibits excellent antimetastasis activity in the experimental B16 melanoma lung metastasis model .

HY-112052

Aminomalonic acid 1 Publications Verification	Endogenous Metabolite	Cancer
Aminomalonic acid is an amino endogenous metabolite, acts as a strong inhibitor of L-asparagine synthetase from Leukemia 5178Y/AR (K_i= 0.0023 M) and mouse pancreas (K_i= 0.0015 M) in vitro. Aminomalonic acid is a potential biomarker to discriminate between different stages of melanoma metastasis .

HY-156247

IVMT-Rx-3	SDCBP NF-κB MMP	Cancer
IVMT-Rx-3 is a inhibitor of SDCBP targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis ^[1]

HY-124875

Arylsulfonamide 64B HIF inhibitor 64B	HIF/HIF Prolyl-Hydroxylase	Neurological Disease
Arylsulfonamide 64B (HIF inhibitor 64B) is an inhibitor of the hypoxia-induced factor (HIF)*. Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis* of uveal melanoma mouse model .**

HY-120241

Reticulol K 251-1	Phosphodiesterase (PDE)	Cancer
Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .

HY-119261

Ruboxyl	Antibiotic	Cancer
Ruboxyl is an anthracycline antibiotic with antitumor activity. Ruboxyl inhibits colorectal cancer (CRC) liver metastasis in mice by 84%, suppresses B16 melanoma growth, and increases the survival rate of mice with L1210 or L5178Y leukemia .

HY-B0963R

Cloxiquine (Standard)	Bacterial Fungal Parasite PPAR	Infection Cancer
Cloxiquine (Standard) is the analytical standard of Cloxiquine. This product is intended for research and analytical applications. Cloxiquine (5-Chloro-8-quinolinol) is an antibacterial, antifungal and antiamoebic agent. Cloxiquine can be used for the research of tuberculosis and dermatoses. Cloxiquine suppresses the growth and metastasis of melanoma cells through activation of PPARγ .

HY-139061

Palmitoyl 3-carbacyclic phosphatidic acid	LPL Receptor ROCK	Cancer
Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .

HY-117231

RM 06	Others	Cancer
RM 06 is an immunomodulator with a peptidyl hypoxanthine structure that significantly reduces the number of lung metastases of B16 melanoma cells in mice after lethal irradiation and bone marrow reconstitution by stimulating the activity of natural killer (NK) cells .

HY-150158

TMX-201	Toll-like Receptor (TLR)	Cancer
TMX-201 is a TLR7 ligand-phospholipid conjugate. TMX-201 shows potent immune stimulatory activity. TMX-201 can be used for breast cancer and melanoma research .

HY-156500

ICMT-IN-1	ICMT	Cancer
ICMT-IN-1 (compound 75) is an inhibitor of ICMT (IC₅₀=0.0013 μM). ICMT-IN-1 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .

HY-155433

ICMT-IN-30	ICMT	Cancer
ICMT-IN-30 (compound 67) is an inhibitor of ICMT (IC₅₀=0.27 μM) .

HY-157092A

(S)-ICMT-IN-3	ICMT	Cancer
(S)-ICMT-IN-3 (compound ent 1-27) is an inhibitor of ICMT (IC₅₀=0.23 μM) .

HY-155431

ICMT-IN-28	ICMT	Cancer
ICMT-IN-28 (compound 65) is an inhibitor of ICMT (IC₅₀=0.008 μM) .

HY-157120

ICMT-IN-52	ICMT	Cancer
ICMT-IN-52 (compound 44) is an inhibitor of ICMT (IC₅₀=0.052 μM) .

HY-155419

ICMT-IN-5	ICMT	Cancer
ICMT-IN-5 (compound 46) is an inhibitor of ICMT (IC₅₀=0.3 μM) .

HY-157103

ICMT-IN-34	ICMT	Cancer
ICMT-IN-34 (compound 39) is an inhibitor of ICMT (IC₅₀=0.17 μM) .

HY-157119

ICMT-IN-51	ICMT	Cancer
ICMT-IN-51 (compound 43) is an inhibitor of ICMT (IC₅₀=0.55 μM) .

HY-149705

ICMT-IN-7	ICMT	Cancer
ICMT-IN-7 (compound 74) is an inhibitor of ICMT (IC₅₀=0.015 μM). ICMT-IN-7 dose-dependently induces ICMT accumulation in the cytoplasm of HCT-116 cells and inhibits the proliferation of multiple cancer cell lines expressing K-Ras and N-Ras .

HY-157095

ICMT-IN-6	ICMT	Cancer
ICMT-IN-6 (compound 29) is an inhibitor of ICMT (IC₅₀=0.09 μM) .

HY-157118

ICMT-IN-50	ICMT	Cancer
ICMT-IN-50 (compound 3) is an inhibitor of ICMT (IC₅₀=0.31 μM) .

HY-155429

ICMT-IN-24	ICMT	Cancer
ICMT-IN-24 (compound 63) is an inhibitor of ICMT (IC₅₀=0.19 μM) .

HY-155424

ICMT-IN-15	ICMT	Cancer
ICMT-IN-15 (compound 51) is an inhibitor of ICMT (IC₅₀=0.032 μM) .

HY-155422

ICMT-IN-13	ICMT	Cancer
ICMT-IN-13 (compound 49) is an inhibitor of ICMT (IC₅₀=0.47 μM) .

HY-157114

ICMT-IN-46	ICMT	Cancer
ICMT-IN-46 (compound 25) is an inhibitor of ICMT (IC₅₀=0.556 μM) .

HY-157105

ICMT-IN-37	ICMT	Cancer
ICMT-IN-37 (compound 41) is an inhibitor of ICMT (IC₅₀=0.308 μM) .

HY-155430

ICMT-IN-27	ICMT	Cancer
ICMT-IN-27 (compound 64) is an inhibitor of ICMT (IC₅₀=0.1 μM) .

HY-155427

ICMT-IN-20	ICMT	Cancer
ICMT-IN-20 (compound 54) is an inhibitor of ICMT (IC₅₀=0.682 μM) .

HY-157112

ICMT-IN-44	ICMT	Cancer
ICMT-IN-44 (compound 23) is an inhibitor of ICMT (IC₅₀=0.167 μM) .

HY-157092B

(R)-ICMT-IN-3	ICMT	Cancer
(R)-ICMT-IN-3 (compound ent 2-27) is an inhibitor of ICMT (IC₅₀=0.01 μM) .

HY-157104

ICMT-IN-36	ICMT	Cancer
ICMT-IN-36 (compound 40) is an inhibitor of ICMT (IC₅₀=0.181 μM) .

HY-149706

ICMT-IN-12	ICMT	Cancer
ICMT-IN-12 (compound 78) is an inhibitor of ICMT (IC₅₀=0.42 μM) .

HY-157096

ICMT-IN-8	ICMT	Cancer
ICMT-IN-8 (compound 30) is an inhibitor of ICMT (IC₅₀=0.652 μM) .

HY-149707

ICMT-IN-21	ICMT	Cancer
ICMT-IN-21 (compound 6ag) is an ICMT inhibitor (IC₅₀=8.8 μM), a sulfonamide-modified farnesyl cysteine (SMFC). The farnesyl and carboxylic acid motifs of ICMT-IN-21 are important structures for inhibiting ICMT .

HY-155425

ICMT-IN-17	ICMT	Cancer
ICMT-IN-17 (compound 52) is an inhibitor of ICMT (IC₅₀=0.38 μM) .

HY-157102

ICMT-IN-26	ICMT	Cancer
ICMT-IN-26 (compound 38) is an inhibitor of ICMT (IC₅₀=0.36 μM) .

HY-157098

ICMT-IN-16	ICMT	Cancer
ICMT-IN-16 (compound 33) is an inhibitor of ICMT (IC₅₀=0.131 μM) .

HY-157109

ICMT-IN-41	ICMT	Cancer
ICMT-IN-41 (compound 20) is an inhibitor of ICMT (IC₅₀=0.069 μM) .

HY-155434

ICMT-IN-31	ICMT	Cancer
ICMT-IN-31 (compound 68) is an inhibitor of ICMT (IC₅₀=0.0038 μM) .

HY-149730

ICMT-IN-54	ICMT	Cancer
ICMT-IN-54 (compound 7c) is an adamantyl analogue and an ICMT inhibitor (IC₅₀=12.4 μM), which can inhibit ICMT Methylation. ICMT-in-54 inhibits BFC (N-biotinyl-(6-aminohexanoic)-S-farnesyl-L-cysteine) methylation in saccharomyces cerevisiae expressing ICMT, which is an indirect effect of inhibiting ICMT methylation .

HY-157099

ICMT-IN-18	ICMT	Cancer
ICMT-IN-18 (compound 35) is an inhibitor of ICMT (IC₅₀=0.066 μM) .

HY-157108

ICMT-IN-40	ICMT	Cancer
ICMT-IN-40 (compound 19) is an inhibitor of ICMT (IC₅₀=0.031 μM) .

HY-155421

ICMT-IN-11	ICMT	Cancer
ICMT-IN-11 (compound 48) is an inhibitor of ICMT (IC₅₀=0.031 μM) .

HY-155432

ICMT-IN-29	ICMT	Cancer
ICMT-IN-29 (compound 66) is an inhibitor of ICMT (IC₅₀=0.019 μM) .

HY-157106

ICMT-IN-38	ICMT	Cancer
ICMT-IN-38 (compound 42) is an inhibitor of ICMT (IC₅₀=0.049 μM) .

HY-157111

ICMT-IN-43	ICMT	Cancer
ICMT-IN-43 (compound 22) is an inhibitor of ICMT (IC₅₀=0.04 μM) .

Cat. No.	Product Name	Target	Research Area

HY-P10542

Dodecapeptide AR71	Peptides	Cancer
Dodecapeptide AR71 is an inhibitor of melanoma inhibitory activity (MIA). Dodecapeptide AR71 can reduce cell migration, reduce metastasis formation, and increase immune response. Dodecapeptide AR71 can be used in research on the treatment of malignant melanoma .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Melanoma Metastasis

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products